Galapagos NV ADR

$27.71
(as of Jun 25, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Galapagos NV ADR

Stock Price
$27.71
Ticker Symbol
GLPG
Exchange
NASDAQ

Industry Information for Galapagos NV ADR

Sector
Healthcare
Industry
Biotechnology

Company Description for Galapagos NV ADR

Website
https://www.glpg.com
Country
USA
Full Time Employees
704

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Fundamentals for Galapagos NV ADR

Market Capitalization
$1,806,791,168
EBITDA
$-276,281,760
Dividends per Share
P/E Ratio
Forward P/E Ratio
166.67
Earnings per Share
$-3.15
Earnings per Share Estimate Next Year
Profit Margin
-58.83%
Shares Outstanding
65,897,100
Percent Owned by Insiders
0.00%
Percent Owned by Institutions
22.24%
52-Week High
52-Week Low

Technical Indicators for Galapagos NV ADR

50-Day Moving Average
200-Day Moving Average
RSI
48.23
ATR
0.71

Analyst Ratings for Galapagos NV ADR

Strong Buy
0
Buy
0
Hold
4
Sell
1
Strong Sell
1

News About Galapagos NV ADR

Jun 23, 2025, 1:30 AM EST
Galapagos NV See more.
Jun 18, 2025, 4:01 PM EST
Galapagos NV See more.
Jun 17, 2025, 12:22 AM EST
Key Insights See more.
Jun 13, 2025, 10:26 AM EST
(RTTNews) - Galapagos NV (GLPG), is slated to present new clinical data from its ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 at the 30th European Hematology Association or EHA Congress. See more.